YD Bio Limited (YDES)
| Market Cap | 977.80M |
| Revenue (ttm) | 510,360 |
| Net Income (ttm) | -1.41M |
| Shares Out | 70.32M |
| EPS (ttm) | -1.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91,502 |
| Open | 13.50 |
| Previous Close | 12.77 |
| Day's Range | 12.77 - 14.88 |
| 52-Week Range | 5.30 - 31.00 |
| Beta | 0.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 30, 2025 |
About YDES
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan. [Read more]
Financial Performance
Financial StatementsNews
YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection
Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and oph...
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics
Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and oph...
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring
Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and o...
YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES
Taipei, Taiwan, Oct. 20, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and o...
YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities
Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and oph...
YD Bio Limited Reports Unaudited Half Year 2025 Financial Results
TAIWAN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophtha...
YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market
Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market Expansion Trading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the N...